EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access

Platelet Reactivity and Sex Differences: Clinical Implications for Women

Anu Aggarwal iD, Tessa J Barrett iD, Puja K Mehta iD, Michael C Honigberg iD, Judith M E M Cosemans iD, Wendy A Goodman iD, Niti R Aggarwal, Michael Holinstat iD, Leslie Cho iD, Scott J Cameron iD, ACC Cardiovascular Disease in Women Committee

Circulation Research · 14.08.2026 · 139 (5)

DOI: 10.1161/circresaha.126.328602 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Circulation Research, erschienen am 14.08.2026. Verfasst von Anu Aggarwal und 10 weiteren Autor:innen. Beteiligte Einrichtung: Cleveland Clinic Research, Heart, Blood, and Kidney Research, Cleveland Clinic Foundation, OH (A.A., S.J.C.). Hauptthemen laut MEDLINE: Platelet Aggregation Inhibitors, Blood Platelets, Thrombosis, Sex Characteristics. Die Arbeit nennt 133 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NHLBI NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Platelets are central to hemostasis and thrombosis. Excessive platelet activation contributes to arterial thrombotic events, including myocardial infarction, ischemic stroke, and complications of peripheral artery disease, whereas excessive platelet inhibition increases bleeding risk. Antiplatelet therapy remains a cornerstone of secondary prevention in atherosclerotic and thrombotic cardiovascular diseases, yet current treatment paradigms do not fully account for biological heterogeneity in platelet function, including differences related to sex, age, hormonal status, and disease context. This state-of-the-art review examines current antiplatelet strategies, fundamental mechanisms of signal transduction, clinical indications, and limitations of preclinical and clinical studies, with a focus on sex-specific considerations and opportunities for personalized antiplatelet therapy. Aspirin and P2Y 12 receptor antagonists are widely used for secondary prevention. However, women have been underrepresented in many pivotal clinical trials, limiting the precision of sex-specific estimates of efficacy and bleeding risk. In parallel, commonly used preclinical models often fail to recapitulate the physiological conditions in which platelets interact with the vasculature, leukocytes, and soluble factors. Emerging therapeutic approaches seek to refine platelet inhibition by targeting pathways that reduce thrombotic risk while preserving hemostasis. Advancing antiplatelet therapy will require integration of mechanistic platelet biology with diverse clinical trial populations, standardized platelet phenotyping, and disease-specific approaches that account for how platelet function is altered across health and vascular disease.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Platelet Aggregation InhibitorsBlood PlateletsThrombosisSex CharacteristicsPlatelet ActivationHumansFemaleAnimalsMaleSex FactorsHemostasis

Stichwörter der Autor:innen

biologyhemostasisleukocytesplatelet activationthrombosis

Substanzen

Platelet Aggregation Inhibitors

Autor:innen und Institutionen

  • Cleveland Clinic Research, Heart, Blood, and Kidney Research, Cleveland Clinic Foundation, OH (A.A., S.J.C.).
  • Leon H. Charney Division of Cardiology, Department of Medicine, Cardiovascular Research Center, New York University Grossman School of Medicine (T.J.B.).
  • Emory Women's Heart Center and Emory Clinical Cardiovascular Research Institute, Emory University School of Medicine, Atlanta, GA (P.K.M.).
  • Division of Cardiology, Department of Medicine, Emory University, Atlanta, GA (P.K.M.).
  • Program in Medical and Population Genetics and the Cardiovascular Disease Initiative, Broad Institute of MIT and Harvard, Cambridge, MA (M.C.H.).
  • Cardiovascular Research Center and Center for Genomic Medicine, Massachusetts General Hospital, Boston (M.C.H.).

ORCID-Profile: Anu Aggarwal, Tessa J Barrett, Puja K Mehta, Michael C Honigberg, Judith M E M Cosemans, Wendy A Goodman, Michael Holinstat, Leslie Cho, Scott J Cameron

Förderung

  • NHLBI NIH HHS

Zitieren

APA

Aggarwal, A., Barrett, T. J., Mehta, P. K., Honigberg, M. C., Cosemans, J. M. E. M., Goodman, W. A., Aggarwal, N. R., Holinstat, M., Cho, L., Cameron, S. J., & ACC Cardiovascular Disease in Women Committee (2026). Platelet Reactivity and Sex Differences: Clinical Implications for Women. Circulation Research, 139(5). https://doi.org/10.1161/circresaha.126.328602

Vancouver

Aggarwal A, Barrett TJ, Mehta PK, Honigberg MC, Cosemans JMEM, Goodman WA, et al. Platelet Reactivity and Sex Differences: Clinical Implications for Women. Circulation Research. 2026;139(5). doi:10.1161/circresaha.126.328602

BibTeX
@article{Aggarwal2026,
  author = {Aggarwal, Anu and Barrett, Tessa J and Mehta, Puja K and Honigberg, Michael C and Cosemans, Judith M E M and Goodman, Wendy A and Aggarwal, Niti R and Holinstat, Michael and Cho, Leslie and Cameron, Scott J and ACC Cardiovascular Disease in Women Committee, ACC Cardiovascular Disease in Women Committee},
  title = {Platelet Reactivity and Sex Differences: Clinical Implications for Women},
  journal = {Circulation Research},
  year = {2026},
  volume = {139},
  number = {5},
  doi = {10.1161/circresaha.126.328602}
}
Kostenlos starten →